Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure  Zuzana Zelinkova, Cokkie van der Ent, Karlien F. Bruin, Onno van Baalen, Hestia G. Vermeulen, Herman J.T. Smalbraak, Rob J. Ouwendijk, Aad C. Hoek, Sjoerd D. van der Werf, Ernst J. Kuipers, C. Janneke van der Woude  Clinical Gastroenterology and Hepatology  Volume 11, Issue 3, Pages 318-321 (March 2013) DOI: 10.1016/j.cgh.2012.10.024 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Effect of IFX (A) and ADA (B) discontinuation during pregnancy on disease activity and complications at retreatment. Disease activity used to guide the decision on discontinuation was determined for IFX at the last infusion in the second trimester and for ADA around gestational weeks 20–24. *Allergic reaction at second infusion of IFX after drug holiday of 22 weeks; second infusion postponed to week 11 because of mastitis. **Both patients had an intensified dosage regimen of ADA. Clinical Gastroenterology and Hepatology 2013 11, 318-321DOI: (10.1016/j.cgh.2012.10.024) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 IFX levels in the cord blood are significantly reduced in the group with more than 10 weeks of time to delivery from IFX discontinuation (early discontinuation), with average cord blood IFX level in early discontinuation group 2.8 ± SEM 1.1 μg/mL vs 10 ± SEM 2.3 μg/mL in late discontinuation group. *Two-sided, unpaired t test. Clinical Gastroenterology and Hepatology 2013 11, 318-321DOI: (10.1016/j.cgh.2012.10.024) Copyright © 2013 AGA Institute Terms and Conditions